PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

Petah Tikva, Israel – July 1 st , 2020 – PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical- stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been